biostudies-literatureUnknown12(8)Montaudon ESignificant rational is available for specific targeting of PI3K/AKT/mTOR pathway in the treatment of non-small cell lung cancer (NSCLC). However, almost all clinical trials that have evaluated Pi3K pathway-based monotherapies/combinations did not observe an improvement of patient's outcome. The aim of our study was therefore to define combination of treatment based on the determination of predictive markers of resistance to the mTORC1 inhibitor RAD001/Everolimus. An <i>in vivo</i> study showed high efficacy of RAD001 in NSCLC Patient-Derived Xenografts (PDXs). When looking at biomarkers of resistance by RT-PCR study, three genes were found to be highly expressed in resistant tumors, i.e., <i>PLK1</i>, <i>CXCR4</i>, and <i>AXL</i>. We have then focused our study on the combination of RAD00Oncotarget859-872https://www.ebi.ac.uk/biostudies/studies/S-EPMC8057272biostudies-literatureHigh <i>in vitro</i> and <i>in vivo</i> synergistic activity between mTORC1 and PLK1 inhibition in adenocarcinoma NSCLC.PMC8057272Deas ORoman-Roman SMontaudon EChapelier ABrevet MGirard NVacher SEl Botty RNaguez ALivartowski AChateau-Joubert SBieche Ide Plater LTreguer DNemati FDaniel CMarangoni EMeseure DDecaudin DZemoura LNicolas ACairo SfalseHigh <i>in vitro</i> and <i>in vivo</i> synergistic activity between mTORC1 and PLK1 inhibition in adenocarcinoma NSCLC.Significant rational is available for specific targeting of PI3K/AKT/mTOR pathway in the treatment of non-small cell lung cancer (NSCLC). However, almost all clinical trials that have evaluated Pi3K pathway-based monotherapies/combinations did not observe an improvement of patient's outcome. The aim of our study was therefore to define combination of treatment based on the determination of predictive markers of resistance to the mTORC1 inhibitor RAD001/Everolimus. An <i>in vivo</i> study showed high efficacy of RAD001 in NSCLC Patient-Derived Xenografts (PDXs). When looking at biomarkers of resistance by RT-PCR study, three genes were found to be highly expressed in resistant tumors, i.e., <i>PLK1</i>, <i>CXCR4</i>, and <i>AXL</i>. We have then focused our study on the combination of RAD002021-01-01T00:00:00Z2021 Apr2026-05-02T10:57:18.081Z2022-02-09T16:05:25.246ZS-EPMC80572723388930610.18632/oncotarget.27930